Pfizer Inc. $PFE Shares Acquired by Fort Washington Investment Advisors Inc. OH

Key Points

• Fort Washington Investment Advisors Inc. increased its ownership stake in Pfizer Inc. by 1.1% in Q2, now holding 1,701,717 shares valued at $41.25 million.
• Analysts have adjusted their price targets for Pfizer, with Citigroup raising it to $26 and Bank of America to $28, while the average target price is now $28.12.
• Pfizer reported earnings of $0.78 per share for the latest quarter, exceeding analyst expectations, and anticipated an EPS of 2.95 for FY 2025.

Fort Washington Investment Advisors Inc. OH lifted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 1.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,701,717 shares of the biopharmaceutical company's stock after buying an additional 18,896 shares during the quarter. Fort Washington Investment Advisors Inc. OH's holdings in Pfizer were worth $41,250,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the 1st quarter worth about $27,000. North Capital Inc. purchased a new stake in Pfizer during the 1st quarter worth approximately $28,000. Bayforest Capital Ltd purchased a new stake in Pfizer during the 1st quarter worth approximately $28,000. Horizon Financial Services LLC purchased a new stake in Pfizer during the 1st quarter worth approximately $35,000. Finally, WPG Advisers LLC purchased a new stake in Pfizer during the 1st quarter worth approximately $35,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on PFE shares. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Bank of America upped their price target on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday. Finally, Morgan Stanley upped their price target on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Stock Performance

NYSE:PFE opened at $23.75 on Friday. The firm has a market capitalization of $135.03 billion, a PE ratio of 12.63, a price-to-earnings-growth ratio of 0.77 and a beta of 0.55. The business's fifty day moving average price is $24.55 and its 200 day moving average price is $24.13. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.